CONMED Q3 Net Income Rises to $19.8 Million Despite Sales Dip, Updates 2026 Guidance

CONMED Corporation (CNMD) reported higher third-quarter 2026 net income on Wednesday despite a slight decline in net sales, and narrowed its full-year guidance ranges. Net income rose to $19.796 million, or $0.66 per share, from $2.859 million, or $0.09 per share, a year earlier. Net sales slipped to $335.557 million from $337.926 million, while gross profit climbed to $189.148 million from $166.119 million and operating income rose to $37.144 million from $11.879 million. For the first nine months, net income increased to $56.695 million from $30.316 million, with EPS at $1.87 versus $0.97, as net sales eased to $996.090 million from $1.002 billion. CONMED now expects 2026 net sales of $1.360 billion to $1.366 billion, compared with a prior range of $1.358 billion to $1.373 billion, and adjusted EPS of $4.54 to $4.61, versus $4.48 to $4.60 previously. CNMD traded after hours at $45.85, up $0.09, or 0.19%, on the Nasdaq.